Health Care & Life Sciences » Biotechnology | BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals Inc. | Ownership

Companies that own BioCryst Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Baker Bros. Advisors LP
14,012,172
12.81%
0
0.65%
06/30/2018
Henderson Global Investors Ltd.
11,096,183
10.14%
3,441,498
0.04%
06/30/2018
RA Capital Management LLC
9,234,692
8.44%
2,250,000
3.65%
08/02/2018
Great Point Partners LLC
7,478,275
6.84%
0
7.34%
07/31/2018
BlackRock Fund Advisors
7,223,431
6.6%
226,888
0%
06/30/2018
Deerfield Management Company LP
6,063,496
5.54%
-1,302,964
1.24%
06/30/2018
The Vanguard Group, Inc.
5,127,944
4.69%
-361,015
0%
06/30/2018
Fidelity Management & Research Co.
4,418,631
4.04%
0
0%
06/30/2018
SSgA Funds Management, Inc.
3,677,404
3.36%
-827,310
0%
06/30/2018
Jennison Associates LLC
3,471,438
3.17%
-33,157
0.02%
06/30/2018

About BioCryst Pharmaceuticals

View Profile
Address
4505 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.biocryst.com
Updated 07/08/2019
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.